Description
Extracorpal shockwave therapy (ESWT) is a non-invasive treatment using sound/pressure waves to stimulate interstitial and extracellular responses with minimal adverse effects. Unlike other treatment modalities, including corticosteroid injection, percutaneous tenotomy and/or orthobiologics, ESWT requires no, to minimal, time away from activities and has been shown to be safely administered even to in-season athletes. The use of ESWT is indicated for various tendon, bone, and/or muscle pathologies. Additionally, ESWT has been proposed as a safe treatment option for osteoarthritis for several years.  Given that ESWT have been more widely utilized to treat various musculoskeletal conditions in recent years; this topic would be of benefit to our members. Having a fundamental understanding the use of ESWT will allow our membership to treat various musculoskeletal conditions which they likely encounter daily. Furthermore, this will allow our colleagues to have other intervention provide a comprehensive treatment plan for our various patient populations.

Learing Objectives
Learning Objective 1: Understand the mechanisms of action of extracorpal shockwave therapy (ESWT) in the treatment of common MSK conditions
Learning Objective 2: Review the clinical applications of ESWT in MSK disorders
Learning Objective 3:Discuss the safety and effectiveness of ESWT in common MSK pathology, including tendinopathies, OA, stress fractures

Member Community:
Sports Medicine

Faculty
Session Director: Cleo Stafford II, MD, MS, FAAPMR: Disclosed no relevant financial relationships.        
Haruki Ishii, MD: Disclosed no relevant financial relationships.    

AAPM&R Medical Education Committee
John C. Cianca, MD: Ownership or partnership with Musculoskeletal Ultrasound Consultants, LLC.
Karen P. Barr, MD: Disclosed no relevant financial relationships.
Rachel A. Brakke Holman, MD: Disclosed no relevant financial relationships.
Joseph E. Burris, MD: Serves on the Speakers Bureau for, and received clinical research grants from Allergan.
David S. Cheng, MD: Disclosed no relevant financial relationships.
Theresa A. Gillis, MD: Disclosed no relevant financial relationships.
Kevin N. Hakimi, MD: Disclosed no relevant financial relationships.
Matthew T. Haas, MD: Disclosed no relevant financial relationships.
R.Samuel Mayer, MD: Royalties from Demos Medical Publishing.
Ameet S. Nagpal, MD MS MEd: Disclosed no relevant financial relationships.
Sunil Sabharwal, MD: Royalities from Demos Publishing; board member, American Board of Physical Medicine and Rehabilitation.
Sarah M. Smith, MD: Disclosed no relevant financial relationships.
Stephanie Tow, MD: Disclosed no relevant financial relationships.
Kevin R. VIncent, MD, PhD: Disclosed no relevant financial relationships.

AAPM&R CME Committee
Karen P. Barr, MD: Disclosed no relevant financial relationships.
Cherry C. Junn, MD: Disclosed no relevant financial relationships.
Sheryl R. Levin, MD: Disclosed no relevant financial relationships.
Kentaro Onishi, DO: Disclosed no relevant financial relationships.
Evan R. Peck, MD: Disclosed no relevant financial relationships.
Cynthia G. Pineda, MD: Disclosed no relevant financial relationships.
Patricia T. Tan, MD: Disclosed no relevant financial relationships.
Brionn K. Tonkin, MD: Disclosed no relevant financial relationships.
Kristin A. Wong, MD: Disclosed no relevant financial relationships.

No other planners, faculty or other individuals in control of content disclosed any relevant financial relationships.

FDA Disclosures
All faculty members for this activity have disclosed they do not intend to discuss or demonstrate any pharmaceutical or medical device for which FDA clearance has not been approved.